We disclose agents that inhibit the expression of NETO-2 which has elevated expression in cancer stem cells the use of NETO-2 as a diagnostic or prognostic marker of tumour initiation the use NETO-2 polypeptides in the identification of agents that inhibit activity and including antibodies that bind NETO-2 and vaccines comprising NETO-2 polypeptides.